Organisation paid for research Program year 2025 Source: CMS Open Payments

Optimed Research, Limited

Neither a doctor nor a teaching hospital

Research payments

$143,495

13 payments

Through program year 2025, Optimed Research, Limited is reported as receiving $143,495 in research payments, across 13 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$19,630	1
2024	Research	$8,557	3
2023	Research	$74,536	4
2022	Research	$22,638	4
2021	Research	$18,134	1

Breakdown

Who paid Research payments · program years 2021–2025

Celgene Corporation $109,395 7 payments
E.R. Squibb & Sons, L.L.C. $34,100 6 payments

Studies the money was for Research payments · program years 2021–2025

Phase III Study - Long Term Extension/Rollover from EE-001 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagiti $53,487 3 payments
Phase III CC-93538 Treat-Through (CC-93538-EE-001) Wk24 PE Primary - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolesc $22,325 1 payment
A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. $19,630 1 payment
A Multi-Center, Multi-National, Randomized, Double $18,134 1 payment
A Multi-Center, Multi-National, Randomized, Double - A Multi-Center, Multi-National, Randomized, Double-Blind, Placebo-Controlled Induction and Long-term Controlled Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects wit $12,449 1 payment
UC Community Study $11,877 1 payment
Phase 1 Drug Interaction (AKA IM042-002) (EOE) $4,762 4 payments
An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice $831 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.